Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab

Iran J Immunol. 2009 Mar;6(1):55-8.

Authors

Ahmad Jalili¹, Tamar Kinaciyan, Talin Barisani, Markus Peck-Radosavljevic, Georg Stingl, Alexandra Geusau, Stefan Wöhrl

Affiliation

¹ Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Allgemeines Krankenhaus, Währinger Gürtel 18-20, A-1090 Vienna, Austria. ahmad.jalili@meduniwien.ac.at

PMID: 19293479

No abstract available

Publication types

Case Reports

MeSH terms

Adenine / analogs & derivatives
Adenine / therapeutic use
Adult
Anti-Inflammatory Agents / therapeutic use
Antibodies, Monoclonal / therapeutic use*
Antiviral Agents / therapeutic use
Behcet Syndrome / complications
Behcet Syndrome / diagnosis
Behcet Syndrome / drug therapy*
HLA-B Antigens / genetics
Hepatitis B / complications
Hepatitis B / drug therapy
Hepatitis B / pathology
Humans
Infliximab
Male
Middle Aged
Organophosphonates / therapeutic use
Reverse Transcriptase Inhibitors / therapeutic use
Tenofovir
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Viral Load

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal
Antiviral Agents
HLA-B Antigens
Organophosphonates
Reverse Transcriptase Inhibitors
Tumor Necrosis Factor-alpha
Tenofovir
Infliximab
Adenine